Product Information
THEOPHYLLINE ER 300 MG TABLET is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.3295 per EA under NDC 62332002531. Its NADAC has been published 545 times since Mar 30, 2016.
FDA first approved this application on Oct 27, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332002531
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
THEOPHYLLINE ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA090430FDA Approved
10/27/2010
TE Code
AB
On Market Since
1/29/2016
Pharmacological Classes
Price Statistics
The NADAC for THEOPHYLLINE ER 300 MG TABLET has been published 545 times since Mar 30, 2016, and over the history we have for it it has risen 9.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3295 per EA |
|---|---|
| All-time high | $3.2010 (Mar 13, 2019) |
| All-time low | $0.3004 (Mar 30, 2016) |
| 52-week high | $0.4924 |
| 52-week low | $0.3196 |
| Median price | $2.4303 |
| Average price | $2.1207 |
| Largest weekly change | +272.4% (May 18, 2016) |
| Weeks tracked | 545 |
| Tracking since | Mar 30, 2016 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Theophylline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Methylxanthine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THEOPHYLLINE ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for THEOPHYLLINE ER 300 MG TABLET, manufactured by Alembic Pharmaceuticals Inc., is $0.3295 per EA (NDC 62332002531), effective Sep 30, 2026.
How has the price of THEOPHYLLINE ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for THEOPHYLLINE ER 300 MG TABLET has risen 9.7%. It has been tracked across 545 weekly CMS publications since Mar 30, 2016.
What are the highest and lowest recorded NADAC prices for THEOPHYLLINE ER 300 MG TABLET?
Since Mar 30, 2016, the NADAC for THEOPHYLLINE ER 300 MG TABLET has ranged from a low of $0.3004 (Mar 30, 2016) to a high of $3.2010 (Mar 13, 2019), with a median of $2.4303 per EA.
Are there cheaper alternatives to THEOPHYLLINE ER 300 MG TABLET?
9 manufacturers publish a NADAC-priced product with the same active ingredient and strength as THEOPHYLLINE ER 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures THEOPHYLLINE ER 300 MG TABLET?
THEOPHYLLINE ER 300 MG TABLET (NDC 62332002531) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.